Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the development of ateganosine (THIO), a first-in-class telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). News about MAIA often centers on clinical milestones, regulatory designations, and financing activities that support its oncology programs.
Investors and observers following MAIA’s news can expect regular updates on its Phase 2 THIO-101 and Phase 3 THIO-104 trials. These items include announcements of first patient dosing, expansion into new countries, enrollment progress, and presentations of trial-in-progress posters at major conferences such as the Society for Immunotherapy of Cancer (SITC), the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and the European Society for Medical Oncology (ESMO) Congress.
MAIA’s press releases, many of which are furnished via Form 8-K filings, also highlight regulatory developments such as the U.S. FDA Fast Track designation for ateganosine in NSCLC and Orphan Drug Designations in additional tumor types. Another recurring theme in the company’s news is insider activity: open-market share purchases by the CEO and directors, and participation by board members in private placement financings, which the company frames as signals of confidence in the ateganosine platform.
On this news page, readers can review MAIA’s announcements related to clinical data signals, trial design details, international site activations, and capital raises that fund key study steps. For those tracking the progress of telomere-targeting approaches in oncology and the later-line NSCLC treatment landscape, MAIA’s news provides an ongoing record of how its investigational therapy is advancing through mid- to late-stage clinical development.
MAIA (NYSE American: MAIA) presented a Trial in Progress poster at the 2025 AACR-NCI-EORTC conference and reported that the first five patients in Part C (expansion) of the THIO-101 Phase 2 trial were enrolled in Taiwan and Turkey as of Oct 27, 2025. The company said screening is ongoing across Europe and Asia and that the safety profile observed so far is well aligned with Parts A and B. The presentation focused on ateganosine (THIO) combined with immune checkpoint inhibitors for advanced NSCLC resistant to prior ICI and chemotherapy. The poster is available at maiabiotech.com/publications.
MAIA Biotechnology (NYSE: MAIA) reported clinical highlights from ESMO Congress 2025 describing extended survival in non-small cell lung cancer (NSCLC) patients treated with ateganosine (THIO).
Key point: as of Sept 17, 2025 one THIO-101 patient who began therapy in March 2023 showed 30 months (912 days) survival; that patient completed treatment after the protocol maximum of two years. MAIA presented two e-posters on Oct 19, 2025 covering the ongoing Phase 2 (THIO-101) and Phase 3 (THIO-104) trials in ICI-resistant advanced NSCLC; posters are available at maiabiotech.com/publications.
MAIA Biotechnology (NYSE American: MAIA) announced a private placement to accredited investors for 603,769 shares of common stock at $1.22 per share, each accompanied by a warrant to buy one share at an exercise price of $1.52. The warrants become exercisable six months after issuance and expire three years from issuance.
The offering is expected to close on or about October 15, 2025, with gross proceeds of approximately $736,600 before offering expenses. The company intends to use net proceeds to fund Step 1 of Part C of the Phase II THIO-101 trial and for working capital. The securities are being offered in a private placement and are unregistered.
MAIA (NYSE American: MAIA) announced on October 7, 2025 a new digital asset treasury strategy permitting corporate officers to buy and sell Bitcoin (BTC), Ethereum (ETH) and USD Coin (USDC).
The Board authorized holdings of up to 90% of the company’s liquid assets in cryptocurrencies and will review transactions, cybersecurity, accounting policies, risks, and material developments. Management said it will keep adequate working capital for operations and seek Board approval to form a Digital Assets Advisory Board to support execution.
MAIA Biotechnology (NYSE American: MAIA) has secured a $2.25 million private placement through the sale of 1,733,766 shares of common stock at $1.30 per share to accredited investors and a Company director.
The offering includes warrants to purchase one share of common stock at $1.57 per share, exercisable after six months with a three-year term. The private placement is expected to close around October 1, 2025. The proceeds will fund Step 1 of Part C of the Phase II THIO-101 trial and working capital needs.
MAIA Biotechnology (NYSE American: MAIA) has secured a $2.3 million NIH grant to expand its THIO-101 Phase 2 clinical trial of ateganosine for advanced non-small cell lung cancer (NSCLC) treatment. The grant will support U.S. patient enrollment over 2025-2027 for third-line treatment of patients resistant to chemo and immunotherapy.
The trial has shown promising results, with median overall survival of 17.8 months in 22 third-line treatment patients, significantly higher than the 5-6 months typical with standard chemotherapy. The trial's expansion phase began in July 2025 in Taiwan, following FDA IND clearance in 2023.
MAIA Biotechnology (NYSE American: MAIA) reported positive Phase 2 clinical trial results for ateganosine (THIO) in combination with cemiplimab for advanced non-small cell lung cancer (NSCLC) patients. The trial showed remarkable efficacy with 5.6 months median progression-free survival in third-line treatment (180 mg dose), more than double the standard of care of 2.5 months.
The study demonstrated an estimated median overall survival of 17.8 months, with confidence intervals showing a lower bound of 12.5 months (95% CI) and 10.8 months (99% CI). Two patients completed 33 treatment cycles, indicating ateganosine's potential for extended dosing. The company has initiated a Phase 2 expansion trial in July 2025 to further validate these promising results.
MAIA Biotechnology (NYSE American: MAIA) announced that its abstract on ateganosine (THIO) treatment for non-small cell lung cancer (NSCLC) has been selected for poster presentation at the 2025 IASLC World Conference on Lung Cancer in Barcelona.
The presentation will highlight promising data from the THIO-101 trial, showing a median overall survival of 17.8 months with a 95% confidence interval lower bound of 12.5 months. Notably, the FDA has recently granted Fast Track designation for ateganosine in NSCLC treatment, potentially expediting its regulatory process towards Accelerated Approval and Priority Review.
MAIA Biotechnology (NYSE American: MAIA) announced the publication of interim clinical data from its Phase 2 THIO-101 trial in the peer-reviewed journal Cells. The manuscript, focused on "Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy," was authored by researchers from Turkey and the U.S., including MAIA's scientific team.
The publication highlights MAIA's novel combination strategy using ateganosine sequenced with a checkpoint inhibitor, which has shown promising results in addressing the challenge of patient resistance to conventional immunotherapies. This development represents a potential breakthrough for patients with high unmet medical needs in non-small cell lung cancer treatment.
MAIA Biotechnology (NYSE American: MAIA) has been granted a European patent for its portfolio of ateganosine-based analogues targeting cancer therapy. The patent covers mercaptopurine ribonucleoside analogues that function as cancer-fighting immunosuppressive agents, disrupting telomere structure and reducing immune system activity to combat cancer cell growth.
The technology, invented by MAIA's CSO Dr. Sergei Gryaznov and Scientific Advisory Board member Dr. Jerry Shay, represents a significant advancement in telomere-targeting compounds with potentially improved cancer cell specificity. The company's global IP portfolio now includes 10 issued patents worldwide, with European validation in 19 countries, and 24 pending patent applications.
FAQ
What is the current stock price of MAIA Biotechnology (MAIA)?
What is the market cap of MAIA Biotechnology (MAIA)?
